
Drug Farm Doses First Patient in Part 3 of Phase 1 Chronic Hepatitis B Trial
Trial will evaluate DF-006, a first-in-class ALPK1 agonist that stimulates local innate immunity in the liver GUILFORD, Conn. & SHANGHAI–(BUSINESS WIRE)–Drug Farm, a clinical-stage biopharmaceutical […]














